Increased Weight Loss With the Combination of Levoketoconazole and Semaglutide in a Patient With Mild Hypercortisolism.

Kargutkar S

AACE endocrinology and diabetes4 Jul 2025

PMID41048691PMCIDPMC12495587DOI10.1016/j.aed.2025.06.009PepBankPUB-41048691

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. 1 result from people.

01HumanCase report or seriesEfficacy outcome
In a 21-year-old woman with obesity and polycystic ovary syndrome, semaglutide (Ozempic) was followed by a 42 lbs weight loss before weight plateaued.
In plain wordsA young woman with obesity lost 42 lbs on semaglutide, then her weight stopped falling.
Peptide
Semaglutide
Outcome
DecreaseWeight loss on Ozempic before plateau
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Studied dose
0.25 mg weekly, titrated up to 1 mg weekly · subcutaneousAs given in this study (human).
Measurements
Weight loss
42 lbs
Ozempic
Source sentences
Summary
The patient lost 42 lbs with Ozempic but plateaued.
2 context sentences(design, population, supporting numbers)
Summary · context
Medications included sertraline 100 mg daily and metformin 500 mg daily, which was increased; spironolactone was added, and Ozempic 0.25 mg subcutaneously weekly was started and titrated up to 1 mg subcutaneously weekly.
Summary · context
A 21-year-old female with a history of polycystic ovary syndrome, anxiety, depression, and obesity presented with irregular menstrual cycles, acne, and excess body hair.
Report a problemFND-4104869101

Studies that did not test the peptide alone2

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

02HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome
In a 21-year-old woman with mild hypercortisolism, adding levoketoconazole to semaglutide was followed by 47 lbs more weight loss (89 lbs in total).
In plain wordsIn a young woman, weight fell by 47 lbs more after levoketoconazole was added to semaglutide; the effect cannot be split between the two drugs.
Peptide
Semaglutide
Outcome
DecreaseAdditional weight loss with levoketoconazole plus semaglutide
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Measurements
Additional weight loss
47 lbs
levoketoconazole plus semaglutide
Total weight loss
89 lbs
levoketoconazole plus semaglutide
Source sentences
Summary
The patient lost an additional 47 lbs, resulting in a total weight loss of 89 lbs while on levoketoconazole and semaglutide, and the cortisol levels normalized.
1 context sentence(design, population, supporting numbers)
Summary · context
A 21-year-old female with a history of polycystic ovary syndrome, anxiety, depression, and obesity presented with irregular menstrual cycles, acne, and excess body hair.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4104869102
03HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome
In a 21-year-old woman with mild hypercortisolism, cortisol levels normalised while she took levoketoconazole and semaglutide.
In plain wordsIn a young woman, cortisol levels returned to normal while she took levoketoconazole and semaglutide together.
Peptide
Semaglutide
Outcome
DecreaseCortisol normalisation with levoketoconazole plus semaglutide
Study
n = 1
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
The patient lost an additional 47 lbs, resulting in a total weight loss of 89 lbs while on levoketoconazole and semaglutide, and the cortisol levels normalized.
1 context sentence(design, population, supporting numbers)
Summary · context
A 21-year-old female with a history of polycystic ovary syndrome, anxiety, depression, and obesity presented with irregular menstrual cycles, acne, and excess body hair.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4104869103

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.